Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells

用于表征循环肿瘤细胞的多相微流体装置

• 批准号: 8657926
• 负责人: John Zhong
• 金额: $ 32.88万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8657926
• 关键词: Affect; Biochemical; Biological; Biological Models; Bioreactors; Blood; Breast Cancer Cell; Breast Cancer Treatment; Cancer Patient; Cell Separation; Cells; Characteristics; Clinical; Colorectal Cancer; Complementary DNA; Cytolysis; Development; Devices; Diagnostic Procedure; Disease Progression; Docking; ERBB2 gene; Electrodes; Encapsulated; Evaluation; FDA approved; Fluorescence; Flushing; Gene Amplification; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Grant; Hela Cells; Heterogeneity; Hospitals; Individual; Laboratories; Malignant Neoplasms; Malignant neoplasm of prostate; Medicine; Microfluidic Microchips; Microfluidics; Molecular; Molecular Analysis; Molecular Profiling; Monitor; Mutation; Neoplasm Circulating Cells; Neoplasm Metastasis; Oils; Optics; Patients; Phase; Physicians; Prevalence; Primary Neoplasm; Process; Reverse Transcription; System; Technology; Testing; Trastuzumab; Travel; United States Food and Drug Administration; base; cancer diagnosis; cancer therapy; cell analyzer; clinical application; design; insight; malignant breast neoplasm; nanolitre; novel; operation; outcome forecast; prototype; success; tool; tumorigenesis

DESCRIPTION (provided by applicant): Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells in Breast Cancer Oncogenesis is a multi-step process leading to a variety of genetic changes with alterations in the transcriptome, and adaptive changes responding to treatments. Therefore, monitoring the dynamic alteration of cancer is critical for cancer treatment. We have integrated multiple microfluidic modules developed in our R21 into a Multi-Phase Single Cell Analyzer (MSCA) for circulating tumor cells (CTC) enumeration and single CTC characterization. Combining the robustness of microstructure, preciseness of optical manipulation and mobility of droplet, the integrated MSCA isolates and encapsulates individual CTC into droplets for nanoliter molecular analysis. With the ability to characterize CTC in routine blood draws, the integrated platform will transform the minimal invasive CTC assessment into a powerful tool for cancer treatment evaluation in hospitals and clinical laboratories, and realize personalized medicine for cancer treatment.

描述(申请人提供)：多相微流控设备用于表征乳腺癌发生中的循环肿瘤细胞是一个多步骤的过程，导致随着转录组的改变而发生的各种基因变化，以及对治疗做出反应的适应性变化。因此，监测肿瘤的动态变化对癌症的治疗至关重要。我们将R21中开发的多个微流控模块集成到多相单细胞分析仪(MSCA)中，用于循环肿瘤细胞(CTC)计数和单个CTC表征。集成的MSCA结合了微观结构的健壮性、光学操作的精确性和液滴的流动性，将单个CTC分离并封装成液滴，用于纳升分子分析。有能力在例行程序中表征CTC 通过抽血，综合平台将把微创CTC评估转变为医院和临床实验室癌症治疗评估的有力工具，实现癌症治疗的个性化用药。